|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-4-19
|
|
pubmed:abstractText |
Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine patients received deep subcutaneous lanreotide injections every 28 days. Twelve patients started on 120 mg lanreotide and forty-seven started on 90 mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120 mg based on insulin-like growth factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-naïve or not currently taking long-acting octreotide ("other"; n = 26). The key endpoints included the percentage of patients/partners able to self- or partner-inject lanreotide and those with normal IGF-1 or growth hormone (GH) levels at week 24/early termination. 100% of patients/partners correctly self- (n = 41) or partner-injected (n = 18) lanreotide by week 4. By week 24/early termination, IGF-1 levels were controlled in 93.7% of switch and 46.2% of "other" patients, while GH levels were controlled in 76.9% and 39.1% of patients, respectively. Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of "other" patients. Most switch patients (81%) reported they preferred lanreotide over long-acting octreotide for future use (P = 0.0001). Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-naïve patients with acromegaly.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-11788630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-15827109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-16268802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-16322377,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-17167139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-17495423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-17892497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-18080837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-18348909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-18492760,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-18997495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-19033371,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19898989-9745397
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1573-7403
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
115-22
|
|
pubmed:dateRevised |
2010-9-28
|
|
pubmed:meshHeading |
pubmed-meshheading:19898989-Acromegaly,
pubmed-meshheading:19898989-Adult,
pubmed-meshheading:19898989-Aged,
pubmed-meshheading:19898989-Drug Administration Schedule,
pubmed-meshheading:19898989-Female,
pubmed-meshheading:19898989-Human Growth Hormone,
pubmed-meshheading:19898989-Humans,
pubmed-meshheading:19898989-Injections, Subcutaneous,
pubmed-meshheading:19898989-Insulin-Like Growth Factor I,
pubmed-meshheading:19898989-Male,
pubmed-meshheading:19898989-Middle Aged,
pubmed-meshheading:19898989-Peptides, Cyclic,
pubmed-meshheading:19898989-Somatostatin,
pubmed-meshheading:19898989-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
|
|
pubmed:affiliation |
Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. salvator@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
